Newcastle RDTC evaluation: the use of aprepitant for the prevention of chemotherapy induced nausea and vomiting

Source: Regional Drug and Therapeutics Centre

Date published: 07/05/2009 17:58

Summary

by: Devika Sennik

The Newcastle Regional Drug and Therapeutics Centre (RDTC) has published an evaluation on the use of aprepitant for the prevention of chemotherapy induced nausea and vomiting.

About this library entry

Category: 4.6 Drugs used in nausea and vertigo | Drug reviews | New drugs | Oncology

NeLM area: Evidence > Drug Specific Reviews

Evaluation

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

4.6 Drugs used in nausea and vertigo

08/11/2011

SMC does not recommend aprepitant (Emend®) for the prevention of chemotherapy-induced nausea and vomiting

07/03/2011

SMC accepts fosaprepitant dimeglumine (IVEmend®) for prevention of nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy

08/02/2011

New CKS Topic: benign paroxysmal positional vertigo

Oncology

09/02/2012

London Cancer New Drugs Group Rapid Review: Cabazitaxel for the second-line treatment of hormone-refractory metastatic prostate cancer

09/02/2012

London Cancer New Drugs Group Rapid Review: Everolimus for advanced pancreatic neuroendocrine tumours (pNET)

09/02/2012

London Cancer New Drugs Group Rapid Review: Erlotinib for the third or fourth-line treatment of NSCLC

Back

Search the NeLM

Medicines A-Z

Preview your comment

Add new comment

Comments